We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
Read MoreHide Full Article
Key Takeaways
Agios' Pyrukynd and Aqvesme generated $44.7 million in Q2 2026 revenue, up 259.3% year over year.
Aqvesme gained early U.S. adoption, with 442 cumulative prescriptions by June 30, 2026.
Mitapivat's SCD opportunity faces competition as Novo Nordisk advances etavopivat toward approval.
Agios Pharmaceuticals (AGIO - Free Report) is entering an important phase of its growth story as its lead therapy, mitapivat, expands across multiple blood disorders. The drug is marketed as Pyrukynd for pyruvate kinase (PK) deficiency and as Aqvesme for thalassemia in the United States. Outside the United States, mitapivat continues to be marketed as Pyrukynd for both indications. Agios is also seeking to expand mitapivat into sickle cell disease (SCD).
However, setbacks in its pipeline and growing competition in SCD have increased the company’s reliance on mitapivat’s commercial performance.
Mitapivat Products Drive Agios’ Top-line Growth
Agios’ commercial momentum accelerated in January 2026 following the U.S. launch of Aqvesme for adults with alpha- or beta-thalassemia. Pyrukynd and Aqvesme together generated $44.7 million in worldwide net revenues in the second quarter of 2026, up 259.3% year over year. The increase is particularly notable because Aqvesme was still in the early stages of its U.S. launch during the quarter.
Aqvesme showed early physician adoption, with 442 cumulative prescriptions from REMS-certified U.S. physicians as of June 30, 2026, compared with 242 at the end of the first quarter. Continued growth in prescriptions could support further patient starts and increase the drug’s contribution to Agios’ revenues.
The international opportunity is also expanding. In May 2026, the European Commission approved Pyrukynd for thalassemia, providing Agios with another avenue for increasing mitapivat sales outside the United States.
The next major opportunity for mitapivat is its potential entry into the SCD market. Agios submitted a supplemental new drug application for mitapivat in SCD under the accelerated approval pathway. The FDA has granted priority review to the filing, with a final decision expected by Nov. 1, 2026.
The discontinuation of tebapivat, Agios’ investigational next-generation PK activator after setbacks in lower-risk myelodysplastic syndromes (LR-MDS) and SCD in mid-2026, has removed a next-generation growth driver. As a result, AGIO is heavily dependent on mitapivat for its near- to medium-term commercial growth.
AGIO Faces Competition in Target Markets
Agios faces competition from established and emerging therapies across its target markets.
Novo Nordisk (NVO - Free Report) is developing etavopivat, an investigational drug with a mechanism of action similar to that of Pyrukynd, which is being evaluated for SCD in late-stage development. Following encouraging late-stage data, Novo Nordisk plans to seek regulatory approval for etavopivat in the fourth quarter of 2026, potentially intensifying competitive pressure on Agios’ mitapivat program in SCD.
Agios also faces competition from therapies developed by major pharmaceutical companies, including Bristol Myers Squibb (BMY - Free Report) , Merck, Pfizer, Novartis (NVS - Free Report) and Vertex, as well as emerging treatments from smaller biotechnology companies. These companies are developing or marketing therapies for genetically defined and blood-related disorders that overlap with Agios’ target markets.
In thalassemia, one of the key competitors is Bristol Myers Squibb’s Reblozyl (luspatercept), an injectable erythroid maturation agent approved in the United States for anemia in adults with beta-thalassemia who require regular red-blood-cell transfusions, as well as certain adults with LR-MDS. Bristol Myers Squibb is expanding Reblozyl’s potential use. In February 2026, the company reported positive phase II results in alpha-thalassemia, including benefits in both non-transfusion-dependent and transfusion-dependent patients. If approved for SCD, Agios could face stiff competition from Novartis’ Adakveo, which is already approved for the said indication.
View the Zacks #1 Rank List
Image: Bigstock
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
Key Takeaways
Agios Pharmaceuticals (AGIO - Free Report) is entering an important phase of its growth story as its lead therapy, mitapivat, expands across multiple blood disorders. The drug is marketed as Pyrukynd for pyruvate kinase (PK) deficiency and as Aqvesme for thalassemia in the United States. Outside the United States, mitapivat continues to be marketed as Pyrukynd for both indications. Agios is also seeking to expand mitapivat into sickle cell disease (SCD).
However, setbacks in its pipeline and growing competition in SCD have increased the company’s reliance on mitapivat’s commercial performance.
Mitapivat Products Drive Agios’ Top-line Growth
Agios’ commercial momentum accelerated in January 2026 following the U.S. launch of Aqvesme for adults with alpha- or beta-thalassemia. Pyrukynd and Aqvesme together generated $44.7 million in worldwide net revenues in the second quarter of 2026, up 259.3% year over year. The increase is particularly notable because Aqvesme was still in the early stages of its U.S. launch during the quarter.
Aqvesme showed early physician adoption, with 442 cumulative prescriptions from REMS-certified U.S. physicians as of June 30, 2026, compared with 242 at the end of the first quarter. Continued growth in prescriptions could support further patient starts and increase the drug’s contribution to Agios’ revenues.
The international opportunity is also expanding. In May 2026, the European Commission approved Pyrukynd for thalassemia, providing Agios with another avenue for increasing mitapivat sales outside the United States.
The next major opportunity for mitapivat is its potential entry into the SCD market. Agios submitted a supplemental new drug application for mitapivat in SCD under the accelerated approval pathway. The FDA has granted priority review to the filing, with a final decision expected by Nov. 1, 2026.
The discontinuation of tebapivat, Agios’ investigational next-generation PK activator after setbacks in lower-risk myelodysplastic syndromes (LR-MDS) and SCD in mid-2026, has removed a next-generation growth driver. As a result, AGIO is heavily dependent on mitapivat for its near- to medium-term commercial growth.
AGIO Faces Competition in Target Markets
Agios faces competition from established and emerging therapies across its target markets.
Novo Nordisk (NVO - Free Report) is developing etavopivat, an investigational drug with a mechanism of action similar to that of Pyrukynd, which is being evaluated for SCD in late-stage development. Following encouraging late-stage data, Novo Nordisk plans to seek regulatory approval for etavopivat in the fourth quarter of 2026, potentially intensifying competitive pressure on Agios’ mitapivat program in SCD.
Agios also faces competition from therapies developed by major pharmaceutical companies, including Bristol Myers Squibb (BMY - Free Report) , Merck, Pfizer, Novartis (NVS - Free Report) and Vertex, as well as emerging treatments from smaller biotechnology companies. These companies are developing or marketing therapies for genetically defined and blood-related disorders that overlap with Agios’ target markets.
In thalassemia, one of the key competitors is Bristol Myers Squibb’s Reblozyl (luspatercept), an injectable erythroid maturation agent approved in the United States for anemia in adults with beta-thalassemia who require regular red-blood-cell transfusions, as well as certain adults with LR-MDS. Bristol Myers Squibb is expanding Reblozyl’s potential use. In February 2026, the company reported positive phase II results in alpha-thalassemia, including benefits in both non-transfusion-dependent and transfusion-dependent patients. If approved for SCD, Agios could face stiff competition from Novartis’ Adakveo, which is already approved for the said indication.